rs2234714 — ABCG1 ABCG1 promoter variant

Intronic ABCG1 variant near the promoter region; homozygous carriers of the minor A allele showed a 36% lower odds of coronary artery disease in a Chinese Han cohort, suggesting a modest protective effect linked to the ABCG1 cholesterol efflux locus.

See your personal result for ABCG1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ABCG1 Promoter — A Tagging Variant in the Cholesterol Efflux Locus

ABCG1 (ATP-binding cassette transporter G111 ATP-binding cassette transporter G1
a membrane protein that pumps cholesterol from macrophages and other peripheral cells onto HDL particles in the bloodstream) is one of two key transporters that drive reverse cholesterol transport — the pathway that clears excess cholesterol from arterial walls and returns it to the liver for disposal. rs2234714 sits in an intronic region of the ABCG1 gene approximately 768 base pairs upstream of a transcribed region, tagging the same chromosomal segment as other ABCG1 promoter variants that have been linked to coronary artery disease (CAD) susceptibility.

The variant does not appear to alter ABCG1 transcription directly — a luciferase reporter assay found no functional effect from this specific position. Its CAD association is therefore most likely due to linkage disequilibrium22 linkage disequilibrium
the non-random co-inheritance of nearby alleles, so that rs2234714 tracks alongside a functionally important nearby variant without itself causing the effect with functionally relevant variants at the ABCG1 promoter locus.

The Mechanism

ABCG1 acts as the second-wave transporter in the two-step cholesterol efflux relay. ABCA133 ABCA1
ATP-binding cassette transporter A1, which initiates reverse cholesterol transport by loading nascent HDL particles starts the process by attaching cholesterol and phospholipids to lipid-poor apolipoprotein A-I. ABCG1 then continues the relay, pumping additional cholesterol onto these maturing HDL particles and enabling them to carry larger cholesterol loads back to the liver.

A functional study of the nearby rs57137919 promoter variant44 functional study of the nearby rs57137919 promoter variant
Liu et al. ABCG1 rs57137919G>A polymorphism is functionally associated with varying gene expression and apoptosis of macrophages. PLoS One, 2014 demonstrated that reduced ABCG1 expression at this locus causes approximately 23% less cholesterol efflux to HDL in macrophages and a 2-fold increase in apoptosis of cholesterol-loaded macrophages — hallmarks of impaired plaque clearance.

Beyond lipid transport, ABCG1 also suppresses the NLRP3 inflammasome55 ABCG1 also suppresses the NLRP3 inflammasome
Westerterp et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis. Circulation, 2018 in macrophages and monocytes. When cholesterol efflux is impaired, intracellular cholesterol accumulation triggers inflammatory cytokine release (IL-1β, IL-18) independently of circulating HDL-C — meaning ABCG1 variants can raise cardiovascular risk through inflammation, not just through lipid channels.

The Evidence

The primary association study66 primary association study
Xu et al. A polymorphism in the ABCG1 promoter is functionally associated with coronary artery disease in a Chinese Han population. Atherosclerosis, 2011 enrolled 1,021 CAD patients and 1,013 controls from a Han Chinese cohort. The rs2234714 A allele was associated with reduced CAD risk in a recessive model (adjusted OR 0.64, p = 0.015), meaning AA homozygotes had approximately 36% lower odds of CAD compared to G-allele carriers. Importantly, the authors found no functional effect of this specific variant in promoter reporter assays.

The evidence is currently limited to this single study in one population. No large European GWAS or replication cohort has independently confirmed the rs2234714 CAD signal. This places the evidence at the emerging level until replicated in independent populations.

A comprehensive pharmacological review77 comprehensive pharmacological review
Frambach et al. Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment. Pharmacol Rev, 2020 reinforces the broader biological relevance of the ABCG1 locus: reduced transporter expression is rate-limiting for reverse cholesterol transport, and pharmacological enhancement of ABCG1 activity is an active therapeutic research direction for atherosclerosis prevention.

Practical Actions

Because rs2234714 is likely a tagging variant, its most actionable implication is that G-allele homozygotes may carry a slightly higher burden of risk variants at the ABCG1 promoter locus. Supporting ABCG1-mediated cholesterol efflux through dietary and lifestyle approaches has the same mechanistic rationale here as for other ABCG1 variants. Omega-3 fatty acids (EPA/DHA) upregulate ABCG1 expression in macrophages through PPAR-gamma and LXR signaling pathways. Monitoring HDL-C as a surrogate for reverse cholesterol transport efficiency is warranted for GG homozygotes.

Interactions

ABCA1 variants (rs2853579, rs4149268) affect the first step of the same cholesterol efflux relay, and compound effects across the ABCA1–ABCG1 pathway are biologically plausible.

Nutrient Interactions

omega-3 fatty acids increased_need

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal

Common ABCG1 genotype — baseline reverse cholesterol transport

You carry two copies of the G allele at rs2234714, the most common genotype globally (~44% of people). In the Chinese Han study, GG carriers formed the reference group against which A-allele carriers were compared. Your ABCG1 function at this locus is not expected to be altered by this specific variant. The broader ABCG1 pathway function is determined by other variants on your haplotype.

AA Beneficial

Two copies of the A allele — associated with lower CAD risk in one population study

The biological mechanism for the protective effect of AA at rs2234714 is not established at this locus specifically.

As an AA homozygote, your ABCG1 locus does not signal elevated CAD risk from this variant. Cardiovascular risk is multifactorial, and standard lipid monitoring remains appropriate.

AG Intermediate

One copy of the A allele — modest trend toward lower CAD risk

The recessive model finding (OR 0.64 for AA) means that one A allele does not produce the same protective effect as two. The biological mechanism for why AA homozygosity might be protective is unclear, since no functional effect was detected at this specific position.